Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Acquisitions & Divestments: 2019-2025

Historic Change in Acquisitions & Divestments for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $61.9 million.

  • Allogene Therapeutics' Change in Acquisitions & Divestments fell 43.61% to $61.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.4 million, marking a year-over-year decrease of 41.20%. This contributed to the annual value of $432.5 million for FY2024, which is 27.66% down from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Change in Acquisitions & Divestments is $61.9 million, which was up 15.08% from $53.8 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Change in Acquisitions & Divestments registered a high of $268.2 million during Q1 2021, and its lowest value of $53.8 million during Q2 2025.
  • Its 3-year average for Change in Acquisitions & Divestments is $109.3 million, with a median of $109.8 million in 2024.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first skyrocketed by 123.06% in 2021, then tumbled by 74.40% in 2022.
  • Allogene Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $82.5 million in 2021, then grew by 20.04% to $99.1 million in 2022, then surged by 37.61% to $136.3 million in 2023, then declined by 25.07% to $102.2 million in 2024, then crashed by 43.61% to $61.9 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $61.9 million for Q3 2025, versus $53.8 million for Q2 2025 and $56.5 million for Q1 2025.